by Richard Daverman, PhD
January 17, 2014 -- Changchun High & New Technology Industries (Group) paid $4.8 million for a 25% interest in Dutch biopharma Mucosis BV. Mucosis is a clinical-stage biotech developing vaccines that can be administered needle-free via the nose or mouth through the mucosal membranes. Changchun is involved in a diverse range of industries, including real estate. Its life science products include generic drugs and biologics as well as TCM preparations. More details....
Help employers find you! Check out all the jobs and post your resume.
